Q4 2019 13F Holders as of 12/31/2019
-
Type / Class
-
Equity / Common stock ("Common Shares")
-
Shares outstanding
-
213M
-
Number of holders
-
77
-
Total 13F shares, excl. options
-
25.2M
-
Shares change
-
+1.19M
-
Total reported value, excl. options
-
$99.5M
-
Value change
-
+$4.79M
-
Put/Call ratio
-
0.24
-
Number of buys
-
31
-
Number of sells
-
-33
-
Price
-
$3.95
Significant Holders of OCULAR THERAPEUTIX, INC - Common stock ("Common Shares") (OCUL) as of Q4 2019
99 filings reported holding OCUL - OCULAR THERAPEUTIX, INC - Common stock ("Common Shares") as of Q4 2019.
OCULAR THERAPEUTIX, INC - Common stock ("Common Shares") (OCUL) has 77 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 25.2M shares
of 213M outstanding shares and own 11.84% of the company stock.
Largest 10 shareholders include Opaleye Management Inc. (5.11M shares), SUMMER ROAD LLC (3.8M shares), BlackRock Inc. (2.83M shares), Versant Venture Management, LLC (2.22M shares), DELTEC ASSET MANAGEMENT LLC (2.12M shares), VANGUARD GROUP INC (2.01M shares), Man Group plc (760K shares), STATE STREET CORP (707K shares), SV Health Investors, LLC (628K shares), and GEODE CAPITAL MANAGEMENT, LLC (571K shares).
This table shows the top 77 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.